종양학 바이오시밀러 시장 보고서 : 약물 유형별, 암 종류별, 유통 채널별, 지역별(2026-2034년)

The global oncology biosimilars market size reached USD 7.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 36.3 Billion by 2034, exhibiting a growth rate (CAGR) of 19.49% during 2026-2034.

Cancer is a lifestyle disease that occurs due to the abnormal growth of cells and may result in the formation of a tumor. At present, most of the effective cancer treatments are based on biological drugs, also known as biologics, and include targeted therapies as well as immunotherapies. These drugs are produced using living organisms, including bacteria, yeast, and animal or plant cells, and require complex manufacturing processes and long development time. As a result, the cost of these drugs is relatively higher, which adds to the expense of cancer treatment. To lower the price of treatment, the interest in the development of biosimilars of branded oncology biologics has been increasing. These biosimilars are highly similar to the reference biologics in terms of effectiveness and safety and can help in significantly reducing the expenditure on cancer treatment due to their lower cost.

Over the years, the rising number of geriatric population and environmental degradation have increased the prevalence of cancer across the globe. These factors, along with the inflating cost of cancer care, have increased the burden on healthcare systems worldwide. Consequently, governing authorities in numerous countries are promoting the uptake of biosimilars as a cost-containment measure. For instance, the United States Food and Drug Administration (USFDA) has developed information materials for physicians and patients to educate them about biosimilars. Apart from this, the availability of affordable medication has also been associated with earlier and wider therapy use as well as improved patient access. Besides this, oncology biosimilars can also increase industry competition, owing to which they have the potential to drive down the prices of biological drugs further. Some of the other growth-inducing factors for the market include approaching patent expiries of branded biologics and increasing research and development (R&D) activities by biosimilar manufacturers.

KEY MARKET SEGMENTATION :

Breakup by Drug Type:

• Monoclonal Antibody
• Immunomodulators
• G-CSF
• Hematopoietic Agents
• Others

Breakup by Cancer Type:

• Lung Cancer
• Colorectal Cancer
• Cervical Cancer
• Breast Cancer
• Kidney Cancer
• Stomach Cancer
• Brain Cancer
• Others

Breakup by Distribution Channel:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Others

Breakup by Region:

• Europe
• Asia Pacific
• North America
• Middle East and Africa
• Latin America

COMPETITIVE LANDSCAPE:

The report has also analyzed the competitive landscape of the market with some of the key players being Biocon Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD Biotechnology Company, Mylan N.V., F. Hoffmann-La Roche AG, etc.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How has the global oncology biosimilars market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global oncology biosimilars industry?
• What are the key regional markets in the global oncology biosimilars industry?
• What is the breakup of the market based on the drug type?
• What is the breakup of the market based on the cancer type?
• What is the breakup of the market based on the distribution channel?
• What are the various stages in the value chain of the global oncology biosimilars industry?
• What are the key driving factors and challenges in the global oncology biosimilars industry?
• What is the structure of the global oncology biosimilars industry and who are the key players?
• What is the degree of competition in the global oncology biosimilars industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Oncology Biosimilars Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Breakup by Drug Type
• 5.5 Market Breakup by Cancer Type
• 5.6 Market Breakup by Distribution Channel
• 5.7 Market Breakup by Region
• 5.8 Market Forecast

6 Market Breakup by Drug Type

• 6.1 Monoclonal Antibody
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Immunomodulators
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 G-CSF
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Hematopoietic Agents
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Others
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Cancer Type

• 7.1 Lung Cancer
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Colorectal Cancer
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Cervical Cancer
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Breast Cancer
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Kidney Cancer
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Stomach Cancer
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast
• 7.7 Brain Cancer
  • 7.7.1 Market Trends
  • 7.7.2 Market Forecast
• 7.8 Others
  • 7.8.1 Market Trends
  • 7.8.2 Market Forecast

8 Market Breakup by Distribution Channel

• 8.1 Hospital Pharmacies
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Online Pharmacies
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Retail Pharmacies
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Region

• 9.1 Europe
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Asia Pacific
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 North America
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Middle East and Africa
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast
• 9.5 Latin America
  • 9.5.1 Market Trends
  • 9.5.2 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Biocon Limited
  • 14.3.2 Celltrion Inc.
  • 14.3.3 Dr. Reddy's Laboratories Ltd.
  • 14.3.4 Intas Pharmaceuticals Ltd.
  • 14.3.5 STADA Arzneimittel AG
  • 14.3.6 Pfizer Inc.
  • 14.3.7 Apotex Inc.
  • 14.3.8 Teva Pharmaceutical Industries Ltd.
  • 14.3.9 Sandoz International GmbH
  • 14.3.10 BIOCAD Biotechnology Company
  • 14.3.11 Mylan N.V.
  • 14.3.12 F. Hoffmann-La Roche AG